ProPhase Labs, Inc.

ProPhase Labs, Inc., formerly known as The Quigley Corporation, is a next-generation biotech, genomics, and consumer products company headquartered in Garden City, New York. The company's mission is to build a healthier world through bold innovation and actionable insight, aiming to revolutionize healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development, and a direct-to-consumer marketing platform for over-the-counter (OTC) dietary supplements.

ProPhase Labs operates across several key segments, including diagnostic services, genomics, biopharma, and consumer products. Its diagnostic offerings have included COVID-19 related clinical diagnostic and testing services, such as PCR and rapid antigen testing. In genomics, the company provides industry-leading Whole Genome Sequencing solutions under the DNA Complete brand, offering deep insights for consumers, universities, and the healthcare industry. The biopharma segment focuses on developing diagnostics and therapeutics for cancer, including a test for the early detection of esophageal cancer (BE-Smart™), and antivirals like Equivir. Its consumer products division includes dietary supplements under the TK supplements brand, such as Legendz XL and Triple Edge XL, available online and in major retail outlets.

Led by CEO and Chairman Ted William Karkus, ProPhase Labs positions itself as a diversified medical science and technology company committed to executional excellence, smart diversification, and a synergistic, omni-channel approach to drive long-term value. Recent corporate activities include reporting year-end 2025 results and highlighting accelerating settlement activity for its Crown Medical Collections Platform in April 2026. The company also provided a business update on advancing Crown Medical Collections activity in March 2026 and initiated a potential sale or strategic partnership for its BE-Smart™ diagnostic in February 2026.